Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar II depression: open-label trial
Aaronson, S.T., van der Vaart, A., Miller, T., LaPratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Sackeim, H.A., Suppes, T. (2024) JAMA Psychiatry , 81(6) , 555-562
Zusammenfassung
Open-label, nonrandomized trial of a single 25 mg dose of synthetic psilocybin with structured psychotherapy in adults with treatment-resistant bipolar II depression. Depressive symptoms improved at 3 and 12 weeks, with no significant increase in mania or suicidality, supporting further controlled studies in this population.
Schlüsselwörter
psilocybinbipolar IIdepressionopen-label trialpsychotherapytreatment-resistantsafetyclinical outcomes
Clinical Research